Breakthrough Properties has announced that Larkspur Biosciences, Incendia Therapeutics, and Deep Genomics will occupy prebuilt suites in its recently redeveloped One Canal building in East Cambridge, Massachusetts. The four-story lab and office building, acquired by Breakthrough in 2021, encompasses 112,000 square feet and features flexible lab and office layouts, a ground floor lounge, fitness center, collaboration spaces, concierge services, a winter garden, and waterfront views. Construction on the remaining two floors will complete by Q1 2025. 

Situated along the First Street corridor near Kendall Square and the Charles River, One Canal offers an amenity-rich environment with proximity to Downtown Boston and major biotech companies like Sanofi and Bristol Myers Squibb.  

Breakthrough, a joint venture of Tishman Speyer and Bellco Capital, is an active life science sector player with over five million square feet of projects in the U.S. and Europe. The firm emphasizes sustainability, targeting LEED Gold and other green certifications.